Literature DB >> 12472796

Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?

Martin Zeier1, Vedat Schwenger, Reinhold Deppisch, Ulrike Haug, Kai Weigel, U Bahner, Christoph Wanner, H Schneider, Thomas Henle, Eberhard Ritz.   

Abstract

BACKGROUND: Glucose degradation products (GDP) are generated in peritoneal dialysis (PD) fluid during heat sterilization and storage. They are thought to adversely affect the peritoneal membrane. The fate of GDP within the peritoneal cavity has not been well characterized.
METHODS: A clinical study was designed to determine (1). whether during the dwell in the peritoneal cavity GDP concentration decreases in the PD fluid as assessed by ex vivo formation of AGE; (2). whether exposure to GDP-containing PD fluids increases plasma fluorescence (as an index of plasma AGE concentration) as well as plasma carboxymethyllysine (CML) concentration; and (3). whether exposure to GDP-containing PD fluids adversely affects glycoprotein CA 125 concentration. A two-group crossover design was adopted comprising two consecutive observation periods of eight weeks each. Stable PD patients were exposed in random order either to conventional PD fluid (heat sterilized at pH 5.5) and subsequently to PD test fluid (or the 2 fluids in reverse order). The PD test fluid was sterilized using a multicompartment bag system separating highly concentrated glucose at pH 3 from the buffer solution. Conventional and test fluids differed with respect to concentrations of GDP, that is, 3-deoxyglucosone (118 vs. 12.3 micromol/L), methylglyoxal (5.3 micromol/L vs. below detection threshold), 3, 4-dideoxyglucosone-3-ene (10 micromol/L vs. below detection threshold) and acetaldehyde (226 vs. <1 micromol/L).
RESULTS: The following results were obtained. First, methylglyoxal disappeared completely as early as two hours after intraperitoneal instillation of conventional PD fluid. Second, when spent conventional dialysate was recovered after a two hour and particularly an eight hour dwell and subsequently incubated ex vivo with 40 mg of human serum albumin, there was a continuous decrease of AGE-forming capacity, that is, less generation of fluorescence (AGE) and pyrraline (non-fluorescent Amadori product), and an increase of advanced oxidation protein products (AOPP) in the spent dialysate. Third, plasma fluorescence (exc. 350/em. 430 nm) as an index of circulating AGE compounds as well as plasma CML concentrations were significantly higher in the conventional PD fluid period versus low GDP PD fluid period. Fourth, CA 125 concentrations in spent dialysate were higher during the low GDP PD fluid period compared to the conventional PD fluid period.
CONCLUSION: Conventional PD fluid undergoes modifications during intraperitoneal dwell with a loss of AGE forming capacity, suggesting breakdown, precipitation or resorption of GDP in vivo. This is accompanied by an increase in plasma AGE compounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12472796     DOI: 10.1046/j.1523-1755.2003.00705.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

1.  Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.

Authors:  Cengiz Candan; Pınar Turhan; Lale Sever; Mahmut Civilibal; Nur Canpolat; Salim Caliskan; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-01-29       Impact factor: 3.714

2.  "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.

Authors:  Caatje Y le Poole; Frans J van Ittersum; Rob M Valentijn; Tom Teerlink; Bengt Lindholm; Piet M Ter Wee; Casper G Schalkwijk
Journal:  Perit Dial Int       Date:  2011-05-31       Impact factor: 1.756

3.  Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.

Authors:  Lars P Kihm; Sandra Müller-Krebs; Julia Klein; Gregory Ehrlich; Laura Mertes; Marie-Luise Gross; Antonysunil Adaikalakoteswari; Paul J Thornalley; Hans-Peter Hammes; Peter P Nawroth; Martin Zeier; Vedat Schwenger
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 4.  New peritoneal dialysis fluids: practical use for children.

Authors:  Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2003-11       Impact factor: 3.714

Review 5.  Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.

Authors:  Anneleen Pletinck; Raymond Vanholder; Nic Veys; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-07-10       Impact factor: 28.314

Review 6.  Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?

Authors:  Murali Krishnan; Paul Tam; George Wu; Andrzej Breborowicz; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

7.  Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids.

Authors:  Rebecca Herzog; Thorsten O Bender; Andreas Vychytil; Katarzyna Bialas; Christoph Aufricht; Klaus Kratochwill
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 8.  Epidemiology of peritoneal dialysis: a story of believers and nonbelievers.

Authors:  Norbert Lameire; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2009-12-15       Impact factor: 28.314

9.  Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study.

Authors:  Sunny Eloot; Raymond Vanholder; Clement Dequidt; Wim Van Biesen
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

10.  Infusion fluids contain harmful glucose degradation products.

Authors:  Anna Bryland; Marcus Broman; Martin Erixon; Bengt Klarin; Torbjörn Lindén; Hans Friberg; Anders Wieslander; Per Kjellstrand; Claudio Ronco; Ola Carlsson; Gabriela Godaly
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.